Jasmine Zhou,
Professor,
University of California-Los Angeles
Xianghong (Jasmine) Zhou is a Professor of Pathology and Lab Medicine at UCLA. Her team developed innovative methods for genome-based diagnostics, network biology, as well as novel approaches to analyze multi-dimensional genomics data. Since four years her lab has been focusing on early cancer detection using liquid biopsy. She served as the contact PI for the NIH Knowledge Base and Coordination Center of the Mechanism-based Disease Connections, and was a standing member of the NIH Biodata Management & Analysis grant review panel (2010-2016). She has previously served as the Head of the Computational Biology and Bioinformatics Program at University of Southern California. She was an associate editor of the journal PLOS Computational Biology and BMC Genomics. She served the program committees and organizing committees of many international conferences. She was a recipient of several awards including an Alfred Sloan fellowship and a NSF Career award.
Ultrasensitive Detection of Cancer Using cfDNA Methylation Sequencing
Wednesday, 27 March 2019 at 14:00
Add to Calendar ▼2019-03-27 14:00:002019-03-27 15:00:00Europe/LondonUltrasensitive Detection of Cancer Using cfDNA Methylation SequencingLiquid Biopsies 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
The detection of tumor-derived cell-free DNA in plasma is one of the
most promising directions in cancer diagnosis. The major challenge in
such an approach is how to identify the tiny amount of tumor DNAs out of
total cell-free DNAs in blood. Here we propose an ultrasensitive cancer
detection method, termed ‘CancerDetector’, using the DNA methylation
profiles of cell-free DNAs. The key of our method is to
probabilistically model the joint methylation states of multiple
adjacent CpG sites on an individual sequencing read, in order to exploit
the pervasive nature of DNA methylation for signal amplification.
Therefore, CancerDetector can sensitively identify a trace amount of
tumor cfDNAs in plasma, at the level of individual reads. Testing
CancerDetector on real plasma data demonstrated its high sensitivity and
specificity in detecting tumor cfDNAs. In addition, the predicted tumor
fraction showed great consistency with tumor size and survival outcome.
Note that all of those testing were performed on sequencing data at low
to medium coverage (1× to 10×). Therefore, CancerDetector holds the
great potential to detect cancer early and cost-effectively.
Add to Calendar ▼2019-03-27 00:00:002019-03-29 00:00:00Europe/LondonLiquid Biopsies 2019Liquid Biopsies 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2019-03-27 14:00:002019-03-27 15:00:00Europe/LondonUltrasensitive Detection of Cancer Using cfDNA Methylation SequencingLiquid Biopsies 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
